Navigation Links
Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
Date:9/9/2008

'The Future Strategies of Cervical Cancer Prevention: What Do We Need to Do Now to Prepare' Forum Facilitates Discussion on the Prevention of Cervical

Cancer in the HPV Vaccine Era

CHICAGO, Sept. 9 /PRNewswire/ -- The Society of Gynecologic Oncologists (SGO) is hosting a Cervical Cancer Prevention Forum on September 12-13, 2008 at the Hotel SAX in Chicago, IL. Approximately 50 key thought leaders will be in attendance to discuss the undefined areas of cervical cancer prevention, identify future research needs and establish follow-up initiatives for the future.

Since the introduction of the prophylactic HPV vaccines, healthcare providers have been faced with a host of questions and challenges concerning the clinical, public health, policy and economic issues regarding the prevention of cervical cancer. SGO, whose vision is "to eradicate gynecologic cancers", felt it was the opportune time to facilitate a larger discussion to answer these mounting questions and provide direction for the future.

"The HPV vaccine is a major technologic advance that has shown considerable promise in preventing the incidence of cervical cancer," states SGO President, Thomas Burke, MD. "As a result, we need to reevaluate the status of cervical cancer by identifying what is needed to more forward to eradicate this women's disease."

SGO invited key representatives from the various populations of clinicians, scientists, physicians and the public policy sector to participate in an informal, interactive discussion moderated by SGO members Levi Downs, MD, Mark Einstein, MD, Thomas Herzog, MD, Warner Huh, MD and Stewart Massad, MD.

"We believe the results of this meeting will have a tremendous impact on the future of cervical cancer prevention," asserts Dr. Herzog, Chair of the SGO Education Committee. "The Forum will redefine clinical, public health, policy and economic issues, as well as create a comprehensive summary to identify future research needs and initiatives."

"There is no time better than now for SGO to host a Forum on the future of cervical cancer prevention," adds Dr. Einstein. "The medical society as a whole has come to a crossroads on how to continue into the future, and SGO is taking a proactive role by leading the future of women's health on a new path."

The Forum's discussions will be captured and shared with the public in the form of a whitepaper to be published soon after the meeting. The whitepaper will detail the Forum's follow-up initiatives, as well as future research needs for attendees and key stakeholder groups working to prevent cervical cancer. The ensuing whitepaper is intended to provide a composite view of the future of cervical cancer screening, prevention and treatment. Professionals dedicated to the prevention of cervical cancer are strongly encouraged to read this summary when released.

The Society of Gynecologic Oncologists (SGO) is a national medical specialty society for physicians trained in the comprehensive management of women's cancers. The Society's membership, totaling more than 1230, is primarily comprised of gynecologic oncologists -- obstetrician/gynecologists with three -- four years of additional, intensive training in the specific study of gynecologic cancers. SGO members provide medical and surgical care to women with ovarian cancer, cervical cancer, endometrial cancer, vulvar cancer, and vaginal cancer. They are trained in chemotherapy and radiation therapy administration, supportive care, and surgery in order to provide comprehensive patient care. More information on gynecologic oncology, the SGO, and its members can be found at http://www.sgo.org.

For more information please contact:

Susan Morris

Society of Gynecologic Oncologists

Phone: 312/235-4060 x244

Fax: 312/235-4059

E-mail: susan.morris@sgo.org


'/>"/>
SOURCE Society of Gynecologic Oncologists
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ApoA-I Data Presented at European Society of Cardiology Congress
2. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
3. Breakthroughs Ahead, Endocrine Society Tells Security Analysts
4. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
5. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
6. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
7. Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada
8. Board Certified Dermatologist and President-Elect of the Dermatologic Society of Greater New York, Dr. Lance H. Brown Takes His Comprehensive Practice to East Hampton, NY
9. Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010
10. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
11. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... (PRWEB) , ... December 03, 2016 , ... ... ground-breaking microbiome studies. A microbiome impact grant award has been made to Dr. ... of heavy smoking and drinking on the oral microbiome. Grant proposals have been ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland ... AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits of a ...
(Date:12/2/2016)... 2, 2016 Amgen (NASDAQ: AMGN ) ... the submission of a Marketing Authorization Application (MAA) to the ... to Avastin ® (bevacizumab). The companies believe this submission ... "The submission of ABP 215 to the ... our oncology portfolio," said Sean E. Harper , M.D., ...
(Date:12/2/2016)... ... 2016 , ... ACEA Biosciences, Inc. announced today that it will be presenting ... the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR ...
Breaking Biology Technology:
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/24/2016)... Calif. , Nov. 23, 2016 Cercacor ... endurance athletes and their trainers non-invasively measure ... Index, Pulse Rate, and Respiration Rate in approximately 30 ... enables users easy and immediate access to key data ... part of a training regimen. Hemoglobin ...
Breaking Biology News(10 mins):